Printer Friendly

Hospira Inc awarded US FDA approval of gemcitabine injection's solution version.

M2 EQUITYBITES-August 8, 2011-Hospira Inc awarded US FDA approval of gemcitabine injection's solution version(C)2011 M2 COMMUNICATIONS http://www.m2.com

Generic pharmaceuticals company Hospira Inc (NYSE:HSP) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) approval to offer gemcitabine injection in a solution formulation for the US oncology market.

The company added solution presentations include 200 mg, 1 gm and 2 gm with a concentration of 38 mg/ml.

Additionally, the company plans to unveil the gemcitabine injection in a solution formulation in early September.

According to the company, the oncology medication recorded US sales of more than USD750m in 2010, led by Eli Lilly's Gemzar.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDAugust 8, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 8, 2011
Words:136
Previous Article:-Fidelity D & D Bancorp sets USD0.25 p/s quarterly dividend.
Next Article:SGOCO Group Ltd names new CFO.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters